BioNxt Solutions (TSE:BNXT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNxt Solutions has advanced its patent protection process for sublingual anticancer drugs aimed at treating autoimmune neurodegenerative diseases, with filings across multiple international jurisdictions. The European Patent Office has positively recognized these patents, which could provide protection until 2045.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.